Johnson & Johnson Innovation kick started 2018 by striking collaborative agreements with 15 different organizations and companies to address areas of high unmet medical need in neuroscience, oncology and other areas.

Shares of Belgium-based TiGenix NV shot up after Japan’s Takeda Pharmaceutical opted to acquire the company for $630 million.

Arvinas inked a deal with Pfizer worth up to $830 million to develop small molecules that can degrade proteins.

Denali Therapeutics – launched in May 2015 by three former Genentech researchers – went public, raising $250 million with shares priced at $18.

Peptidream Inc. scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment of multiple disease targets.

The National Institutes of Health said it had partnered 11 biopharma companies to help advance a new class of drugs that uses the body’s immune system to fight cancer.

The British government has rekindled its industrial strategy, unveiled earlier in 2017 to prepare the economy for Brexit, with plans to boost the country’s pharmaceuticals sector via fresh investments and public-private collaborations.

Dermatologic-focused Aclaris Therapeutics Inc. is expanding its pipeline into new territory with the acquisition of Missouri-based Confluence Life Sciences Inc., a seven-year-old privately held startup focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

MyoKardia simultaneously released positive data from a Phase II clinical trial and its second-quarter 2017 financials.

Astellas Pharma announced that the company is wrapping up its research operations with Santa Monica, Calif.-based Agenus.